Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ReShape Lifesciences Inc

< Previous 1 2 Next >
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Participate in Investor and Industry Conferences in June
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2023 and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® to Present Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the Keystone Symposia on Type 2 Diabetes
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference Call
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.